Amgen Inc. (AMGN) Market Cap, Stock Prices, Chart & Financials

Amgen Inc.
AMGN
$245.4

PriceChangeChange %MarketcapOpenHighLowCloseVolume52 Week RangeEPSDividend RateDividend YieldSectorIndustryEmployeesCountryLast Updated
$245.4$1.90.79%131.1B$246.3$247.1$244.0$243.52,608,701
10.127.222.9649707HealthcareDrug Manufacturers—General24,300United States9 hours ago

Amgen Inc. Market Cap (2001 – 2022)

YearMarket cap
2022$131,108,700,160.0
2021$126.71 B
2020$133.85 B
2019$142.56 B
2018$122.56 B
2017$126.23 B
2016$108.76 B
2015$122.39 B
2014$121.12 B
2013$86.08 B
2012$65.19 B
2011$56.28 B
2010$51.16 B
2009$56.28 B
2008$60.46 B
2007$50.48 B
2006$79.64 B
2005$96.52 B
2004$80.82 B
2003$79.31 B
2002$62.31 B
2001$59.02 B

Amgen Inc. Revenue & Earnings (2001 – 2021)

Amgen Inc. Revenue & Earnings
YearRevenueEarnings
2021$24.36 B$7.62 B
2020$24.24 B$9.39 B
2019$22.20 B$10.42 B
2018$22.53 B$10.93 B
2017$21.79 B$10.90 B
2016$21.89 B$10.42 B
2015$20.94 B$9.07 B
2014$19.32 B$6.65 B
2013$18.19 B$6.28 B
2012$16.63 B$6.06 B
2011$15.58 B$4.61 B
2010$15.05 B$5.92 B
2009$14.64 B$5.72 B
2008$15.00 B$5.21 B
2007$14.77 B$4.77 B
2006$14.06 B$6.17 B
2005$12.43 B$4.84 B
2004$10.54 B$3.90 B
2003$8.44 B$3.09 B
2002$5.52 B$9.29 B
2001$3.76 B$1.53 B

About The Company

Amgen Inc.
Sector: Healthcare
Industry: Drug Manufacturers—General
Exchange: NMS
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

0 Comments

Your email address will not be published.